Goldman Sachs Group Inc - Nov 7, 2023 Form 3 Insider Report for Panbela Therapeutics, Inc. (PBLA)

Role: 10%+ Owner
Signature: /s/ Crystal Orgill, Attorney-in-fact
Stock symbol: PBLA
Transactions as of: Nov 7, 2023
Transactions value $: $0
Form type: 3
Date filed: 11/13/2023, 07:27 PM
Previous filing: Oct 6, 2023
Next filing: Nov 13, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding	PBLA	Common Stock						360K	Nov 7, 2023	See Footnotes	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The Common Stock of the Issuer reported herein as indirectly purchased were beneficially owned directly by Goldman Sachs and indirectly by GS Group.
F2	This statement is being filed by The Goldman Sachs Group, Inc. ("GS Group") and Goldman Sachs & Co. LLC ("Goldman Sachs" and together with GS Group, the "Reporting Persons"). Each Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein. On November 07, 2023, the Reporting Persons experienced an increase in their beneficial ownership of Panbela Therapeutics, Inc. CMN (the "Issuer") to above 10% of the outstanding Common Stock. On November 09, 2023, the Reporting Persons reduced their beneficial ownership to below 10% of the Issuer's outstanding Common Stock.

Content

The Common Stock of the Issuer reported herein as indirectly purchased were beneficially owned directly by Goldman Sachs and indirectly by GS Group.

This statement is being filed by The Goldman Sachs Group, Inc. ("GS Group") and Goldman Sachs & Co. LLC ("Goldman Sachs" and together with GS Group, the "Reporting Persons"). Each Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein. On November 07, 2023, the Reporting Persons experienced an increase in their beneficial ownership of Panbela Therapeutics, Inc. CMN (the "Issuer") to above 10% of the outstanding Common Stock. On November 09, 2023, the Reporting Persons reduced their beneficial ownership to below 10% of the Issuer's outstanding Common Stock.